Evidence map›Paper›PMID 20072663›Full record

ArticleClinical and translational science2009

Sex-specific impact of aldosterone receptor antagonism on ventricular remodeling and gene expression after myocardial infarction.

Rosemeire M Kanashiro-Takeuchi, Bettina Heidecker, Guillaume Lamirault, Jennifer W Dharamsi, Joshua M Hare

Abstract read
In one paragraph

Article in Clinical and translational science, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 69 citations in OpenAlex.

  1. Trial
  2. Review
  3. Female sex hormones do not drive the sex-specific mechanisms of obesity-related hypertension.American journal of physiology. Heart and circulatory physiology · 2025
    Article
  4. Review
  5. Aging and sex differences in salt sensitivity of blood pressure.Clinical science (London, England : 1979) · 2025
    Review
  6. Review
  7. Article
  8. The inflammatory spectrum of cardiomyopathies.Frontiers in cardiovascular medicine · 2024
    Review
  9. Review
  10. Article
  11. Salt Sensitivity of Blood Pressure in Women.Hypertension (Dallas, Tex. : 1979) · 2023
    Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Sexual Dimorphism of Corticosteroid Signaling during Kidney Development.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Rosemeire M Kanashiro-TakeuchiUniversity of Miami, Miller School of Medicine, Miami, Florida, USA.
Bettina Heidecker
Guillaume Lamirault
Jennifer W Dharamsi
Joshua M Hare
University of Miami · USJohns Hopkins University · US

Funding

Cardioprotective Effect of Growth Hormone Releasing HormoneR01HL107110 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI HARE, JOSHUA M · 2011 to 2020
$5.9M
OXIDATIVE STRESS IN HEART FAILURE: MECHANISMSR01HL065455 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI HARE, JOSHUA M · 2000 to 2008
$2.6M
NHLBI NIH HHS R01 HL065455NHLBI NIH HHS R01 HL107110NHLBI NIH HHS R01 HL-65455
6 · The paper itself

Abstract

Aldosterone receptor antagonism reduces mortality and improves post-myocardial infarction (MI) remodeling. Because aldosterone and estrogen signaling pathways interact, we hypothesized that aldosterone blockade is sex-specific. Therefore, we investigated the impact of eplerenone on left ventricular (LV) remodeling and gene expression of male infarcted rats versus female infarcted rats. MI and Sham animals were randomized to receive eplerenone (100 mg/kg/day) or placebo 3 days post-surgery for 4 weeks and assessed by echocardiography. In the MI placebo group, left ventricular end-diastolic dimension (LVEDD) increased from 7.3 +/- 0.4 mm to 10.2 +/- 1.0 mm (p < 0.05) and ejection fraction (EF) decreased from 82.3 +/- 4% to 45.5 +/- 11% (p < 0.05) in both sexes (p = NS between groups). Eplerenone attenuated LVEDD enlargement more effectively in females (8.8 +/- 0.2 mm, p < 0.05 vs. placebo) than in males (9.7 +/- 0.2 mm, p = NS vs. placebo) and improved EF in females (56.7 +/- 3%, p < 0.05 vs. placebo) but not in males (50.6 +/- 3%, p = NS vs. placebo). Transcriptomic analysis using Rat_230-2.0 microarrays (Affymetrix) revealed that in females 19% of downregulated genes and 44% of upregulated genes post-MI were restored to normal by eplerenone. In contrast, eplerenone only restored 4% of overexpressed genes in males. Together, these data suggest that aldosterone blockade reduces MI-induced cardiac remodeling and phenotypic alterations of gene expression preferentially in females than in males. The use of transcriptomic signatures to detect greater benefit of eplerenone in females has potential implications for personalized medicine.

Indexed as

Mineralocorticoid Receptor AntagonistsSex CharacteristicsAnimalsCluster AnalysisEplerenoneFemaleFibrosisGene Expression ProfilingGene Expression RegulationMaleMyocardial InfarctionPlacebosRatsRats, WistarSpironolactoneVentricular RemodelingEplerenoneMineralocorticoid Receptor AntagonistsPlacebosSpironolactonealdosterone antagonismgene expressionheart failuremyocardial infarctionsex

Identifiers

PMID20072663
PMCPMC2805249
OpenAlexW2131268302

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.